The U.S. Food and Drug Administration has approved Regeneron’s antibody therapy for emergency use. It is the same therapy that was administered to US President Donald Trump for coronavirus.
The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York. (Reuters)
Regeneron Pharmaceuticals Inc’s coronavirus antibody therapy was granted emergency use authorisation by the US Food and Drug Administration on Saturday. It is the same treatment that was notably administered to Donald Trump when he was being treated for the coronavirus infection.
Donald Trump had claimed that the therapy helped cure him of the disease.
“Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,” news agency AFP quoted Stephen Hahn, commissioner of the Food and Drug Administration as saying.
What is Regeneron antibody therapy?
Regeneron’s REGEN-COV2 “antibody cocktail” – containing an antibody made by the company and a second isolated from humans who recovered from Covid-19 – is designed so that the two antibodies seek out and bind to the coronavirus’ spike protein to prevent it from entering healthy human cells, news agency Reuters reported.
The FDA said the monoclonal antibodies, casirivimab and imdevimab, should be administered together for the treatment of mild to moderate coronavirus in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19, reported Reuters.
This includes those who are 65 years of age or older or who have certain chronic medical conditions.
The treatment is part of a class of drugs known as monoclonal antibodies, which are manufactured copies of antibodies created by the human body to fight infections.
Is Regeneron effective against coronavirus?
Regeneron said on Saturday the clinical evidence from outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load, reported Reuters.
The company said it expects to have does of REGEN-COV2 treatment ready for about 80,000 patients by the end of this month, about 200,000 patients by the first week of January and approximately 300,000 patients in total by the end of January.
The FDA said the antibodies are not authorized for patients who are hospitalized due to Covid-19 or require oxygen therapy due to coronavirus.
(With inputs from Reuters and AFP)